Search PubMed⌕ Search

Biomedical subjects

R A Kloner

Publications and source records attributed to R A Kloner.

At least 19 recordsLinked to original sources
PubMed1999

Erectile dysfunction and sildenafil citrate and cardiologists.

Since the release of sildenafil citrate (Viagra), increasing numbers of patients are seeking treatment for erectile dysfunction (ED). Many of the risk factors for ED are the same as those for cardiac disease. Sildenafil citrate is a highly effective oral agent for ED. It is absolutely contraindicated in patients receiving organic nitrates. The issue of cardiac deaths associated with sildenafil citrate and ways of potentially minimizing these cases are discussed.

Cardiovascular Diseases↗
PubMed1999

Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both abolished by neomycin in rabbit heart.

The mechanisms responsible for infarct size reduction with preconditioning remain controversial. Our aim was to determine whether release of the second messenger inositol (1,4,5)-triphosphate (Ins(1,4,5)P3) during the preconditioning stimulus may play a role. To test this concept, Langendorff-perfused rabbit hearts underwent sham perfusion, 5 min of coronary artery occlusion (CO), or 5 min of CO + infusion of neomycin, an agent which inhibits formation of Ins(1,4,5)P3. Direct quantitation (by competitive binding assay) revealed a 2-fold increase in Ins(1,4,5)P3 content with brief ischemia vs shams (0.69 +/- 0.14 vs 0.34 +/- 0.05 pmol/mg tissue; p < .05) that was blocked by neomycin (0.15 +/- 0.04 pmol/mg). Infarct size (by tetrazolium staining) was assessed in additional hearts that underwent 30 min of sustained CO and 2 h of reperfusion. As expected, two 5-min episodes of preconditioning ischemia reduced infarct size versus controls (30 +/- 6% versus 63 +/- 3% of the myocardium at risk; p < .01). In contrast, infarct size was comparable (54-56% of the risk region) in neomycin-treated control and preconditioned hearts. These results demonstrate that myocardial Ins(1,4,5)P3 content is increased in response to brief preconditioning ischemia and are consistent with the concept that Ins(1,4,5)P3 may be a potential mediator of infarct size reduction with preconditioning in isolated rabbit heart.

Animals↗
PubMed1999

Myocardial hypothermia: a potential therapeutic technique for acute regional myocardial ischemia.

The importance of temperature in the development of necrosis after myocardial ischemia in the beating heart is becoming apparent. Recent studies have shown that the proportion of the ischemic risk zone that becomes necrotic is directly correlated with temperature. This fact suggests the potential therapeutic benefits of reducing myocardial temperature after coronary artery occlusion. We have shown in a number of experimental protocols in the rabbit model of myocardial infarction that topical regional hypothermia reduces infarct size even when instituted after coronary artery occlusion. The reduction in myocardial temperature required to obtain this benefit is modest ( 30 degrees C to 34 degrees C). Topical regional hypothermia allows targeted cooling of a zone of the heart. Myocardial cooling can also be achieved by perfusing the pericardial sac with a chilled fluid by using a closed-circuit catheter system that does not cause cardiac tamponade. This technique also protects myocardium during ischemia. Myocardial hypothermia might be a useful technique to limit ischemic damage during infarction or as adjunctive therapy during minimally invasive cardiac surgery.

Acute Disease↗
PubMed1998

Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B.

BACKGROUND: The timing of onset of angina before myocardial infarction in relation to outcome is unknown. METHODS AND RESULTS: We prospectively determined the importance of the time of onset of preinfarction angina in relation to 30-day outcomes in the TIMI-9B study from standardized forms. Of the 3002 patients entered into the study, 425 reported angina before their myocardial infarction. Patients with angina onset within 24 hours of infarction had a lower 30-day cardiac event rate (mortality, recurrent myocardial infarction, heart failure, or shock) at 4% than those with onset of angina >24 hours (17%; P=.030). A history of any angina alone was not associated with reduced event rate. Peak creatine kinase levels tended to be lower in the group with angina within 24 hours. These benefits were not due to higher rates of use of antianginal medicines or aspirin and were not a consequence of differences in baseline characteristics or disease states (hypertension, hypercholesterolemia) among subgroups. CONCLUSIONS: These temporal observations are consistent with the concept of preconditioning by preinfarction angina but do not rule out other mechanisms.

Aged↗
PubMed1998

Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine.

BACKGROUND: Recent studies suggest that patients with angina before myocardial infarction exhibit improved recovery of coronary perfusion after thrombolysis by an as-yet-unknown mechanism. We therefore proposed that brief antecedent ischemia/reperfusion may, via release of adenosine, improve vessel patency in damaged and stenotic coronary arteries. METHODS AND RESULTS: Anesthetized dogs underwent coronary injury + stenosis, resulting in repeated cyclic variations in coronary blood flow (CFVs) caused by the formation/dislodgment of platelet-rich thrombi. Vessel patency was assessed for 3 hours after stenosis by quantification of the nadir of the CFVs, duration of total thrombotic occlusion (flow=0), and area of the flow-time profile (expressed as percent of baseline flow x 180 minutes). In protocol 1, dogs received 10 minutes of coronary occlusion + 10 minutes of reflow or a comparable 20-minute control period before injury + stenosis. The median nadir of the CFVs was higher (4.0 versus 0.3 mL/min), median zero flow duration per 30-minute time interval was shorter (0.4 versus 15.1 minutes), and mean percent flow-time area was greater (54+/-8% versus 28+/-9%) in dogs that received antecedent ischemia versus controls (P<.05). These benefits of antecedent ischemia/reperfusion were largely mimicked by a 10-minute intracoronary adenosine infusion (400 microg/min) in lieu of brief ischemia (protocol 2) and were abolished by administration of the adenosine A1/A2 receptor antagonist PD 115,199 (3 mg/kg i.v.) before brief antecedent coronary occlusion (protocol 3). CONCLUSIONS: Brief antecedent ischemia attenuates subsequent platelet-mediated thrombosis in damaged and stenotic canine coronary arteries, due, in large part, to an adenosine-mediated mechanism.

Adenosine↗
PubMed1998

Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.

Issues raised recently concerning the safety of calcium channel blockers (CCBs) prompted an analysis of the occurrence of cardiovascular events and death in the Pfizer Inc. hypertension clinical trial databases for amlodipine (Norvasc) and nifedipine in the gastrointestinal therapeutic system (GITS) formulation (Procardia XL). Prospectively defined analyses of data from comparative and noncomparative trials of amlodipine and nifedipine GITS were conducted. Outcome measures included cardiovascular and noncardiovascular deaths, and adverse cardiovascular events including new/worsened angina, myocardial infarction (MI), serious arrhythmia, stroke, congestive heart failure, and bleeding. Among all amlodipine-treated patients (n = 32,920), the incidence rates for all-cause death, MI, and new/worsened angina were 3.0, 3.3, and 1.6/1,000 patient-years of exposure, respectively. Among those in comparative trials alone (n = 4,126), the all-cause death rate was 4.1/1,000 patient-years, which was comparable to that of other non-CCB agents and significantly less than that of other CCBs (23.8/1,000 patient-years, p = 0.015), although the difference in rates represents only 2 deaths. Among all nifedipine-GITS-treated patients (n = 2,645), the rate of all-cause death was 4.1/1,000 patient-years, of MI 6.5/1,000 patient-years, and of new/ worsened angina 5.7/1,000 patient-years. The incidence rates for MI and other cardiac events were low in these hypertension trials, and did not differ among treatment groups in either the amlodipine or nifedipine GITS comparative analyses. In the clinical trial databases analyzed, there is no signal suggesting excessive risk of death or cardiovascular events for hypertensive patients treated with amlodipine or nifedipine GITS.

Amlodipine↗
PubMed1998

[Cardiomyocyte transplantation--a cell replacement for repair of myocardial infarction?].

Cardiomyocytes lose the ability to proliferate after birth. Subsequently, irreversible cellular damage, e.g., during myocardial infarction, causes loss of functional properties and cell replacement by fibrotic tissue. It is, therefore, not surprising that cell replacement strategies such as cardiomyocyte transplantation in damaged myocardium or scar tissue has gained widespread interest. In other species such as mice, rats, and dogs, the technical feasibility of skeletal myoblast-, satellite cell-, and fetal cardiomyocyte engraftment into normal and diseased myocardium has been demonstrated by simple injection methods. Repeatedly, it has been shown that transplanted cells may survive for weeks within host myocardium and build intercellular connections such as gap junctions and desmosomes. In contrast, grafthost connections have not, as yet, been convincingly demonstrated. Hypothetically, cell transplants might exhibit the following functional properties: stabilization of diseased tissue to prevent structural remodeling; carrier for recombinant proteins, growth factors or drugs to induce molecular alterations of host myocardium; and improvement of regional and global myocardial function due to active contractility. However, clear evidence of coordinated contractility of transplanted cells, and, thus, of a clinically relevant therapeutical use of cardiomyocyte transplantation as a replacement strategy for damaged host cardiac cells, remains to be demonstrated.

Animals↗
PubMed1998

Temporal changes in the subcellular distribution of protein kinase C in rabbit heart during global ischemia.

Our recent studies utilizing an in vivo regional ischemia model revealed no changes in the subcellular distribution of protein kinase C (PKC) in dog and rabbit hearts after repeated 5 min episodes of preconditioning ischemia/reperfusion. However, 10 min of sustained ischemia resulted in an increase in PKC activity in the membrane fraction. These findings indicate that prolonged ischemia may cause changes in the subcellular distribution of PKC. However, the detailed time course of these changes during sustained severe ischemia is poorly resolved. Thus, our objective was to study temporal changes in PKC distribution in the cytosolic, nuclear, and membrane fractions isolated from globally ischemic rabbit heart. Hearts were removed under deep anesthesia, placed into normal saline at 37 degrees C, and repeatedly sampled from apex to base at baseline, 2, 5, and 10 min into global ischemia, with matched samples obtained in every heart. PKC activity was increased at 2 min into global ischemia in both the nuclear fraction (1069 +/- 75 vs. 893 +/- 49 pmol/min/g at baseline; p = 0.05) and the membrane fraction (1374 +/- 95 vs 1187 +/- 59 pmol/min/g at baseline; p < 0.05) with persistent translocation observed at 5 and 10 min into the protocol. Thus, direct biochemical determination of PKC activity in the isolated rabbit heart revealed increased activity in the nuclear and the membrane fractions as early as 2 min into global ischemia.

Animals↗
PubMed1998

Evaluation of cardiac structures and function in small experimental animals: transthoracic, transesophageal, and intraventricular echocardiography to assess contractile function in rat heart.

OBJECTIVES: The efficacy of three different echocardiographic techniques to assess cardiac structures and function in the rat heart was studied. BACKGROUND: With increasing costs for large animal studies there is need for improved assessment of ventricular function in small animal models. METHODS: Transthoracic, transesophageal, or intracavitary echocardiography was performed in 138 rats using either a pediatric or an intravascular ultrasound transducer in control, infarcted, and obese rats. Left ventricular dimensions and wall thickness were measured. RESULTS: Transthoracic echocardiography allows qualitative and quantitative estimation of cardiac dimensions and ventricular function. End-diastolic and end-systolic diameters were 0.53 +/- 0.08 and 0.26 +/- 0.05 cm in controls, 0.63 +/- 0.08 and 0.41 +/- 0.07 cm in infarcted (p < 0.001 vs controls), and 0.66 +/- 0.1 and 0.21 +/- 0.07 cm in obese rats (p < 0.01 vs controls). Fractional shortening was 52 +/- 6% in controls, 36 +/- 5% in infarcted (p < 0.001), and 68 +/- 9% in obese rats (p < 0.001). Wall thickness was increased in obese rats. Transesophageal echocardiography allows a qualitative rather than quantitative assessment. Intracavitary ultrasound enabled visualization of the endocardium. Following coronary occlusion, fractional shortening and ejection fraction were decreased (30.8 +/- 4.5 vs 44.4 +/- 4.7%, p < 0.005, and 46.7 +/- 8.5 vs 63.4 +/- 5.4%, p < 0.005, respectively). CONCLUSIONS: Transthoracic echocardiography is a non-invasive technique to sufficiently provide information about cardiac structures and function, while transesophageal echocardiography allows rather a qualitative estimation of the rat heart. Intracavitary ultrasound can be used to assess the endocardium, ventricular function, and dimensions in open-chest studies in rats.

Animals↗
PubMed1998

A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography.

BACKGROUND: Costs for large animal studies have escalated. Therefore there is a need to develop small animal models of non-ischemic cardiac failure and accurate non-invasive techniques that will allow serial quantitation of left ventricular function. OBJECTIVES: The purpose of our study was to determine the efficacy and reliability of adriamycin for inducing cardiomyopathy in rats. We hypothesized that high frequency transthoracic 2-dimensional and M-mode echocardiography would allow for serial testing of cardiac function in this small animal model. METHODS: Adriamycin was administered at a dose of 2.5 mg/kg intravenously once a week for 10 weeks in 54 rats. Transthoracic echocardiography by use of a 7.5 MHz transducer was performed in 19 rats at baseline and additionally at 12 weeks after beginning of adriamycin therapy to measure left ventricular dimensions and calculate fractional shortening. RESULTS: The mortality rate during the treatment period was 11%, but increased to 52% at 13 weeks. Transthoracic echocardiography provided adequate visualization of left ventricular dimensions and cardiac function in a parasternal short axis view. In follow-up echocardiography, pericardial effusion was detected in 8/19 rats (42%). Compared to baseline, end-diastolic diameters increased from 0.56 +/- 0.06 to 0.64 +/- 0.08 mm (p < 0.001), end-systolic diameters increased from 0.27 +/- 0.03 to 0.42 +/- 0.08 mm (p < 0.001), and fractional shortening decreased from 52.8 +/- 4.0 to 34.3 +/- 7.1% (p < 0.001) at 12 weeks. Electron microscopy in a subset of rats revealed cardiomyocyte degeneration, mitochondrial and sarcoplasmatic reticular edema, numerous intracellular vacuoles and 'onion-ring' shaped mitochondrial cristae, characteristic for adriamycin cardiotoxicity in human patients. CONCLUSION: Adriamycin at an intravenous dose of 2.5 mg/kg over 10 weeks can be used to create a reliable model of non-ischemic dilated cardiomyopathy with a high success rate. For in-vivo diagnostic purposes, transthoracic echocardiography provides a reliable technique to non-invasively assess cardiac function quantitatively and qualitatively in follow-up studies in rat cardiomyopathy. This small animal model can easily be used for testing new therapeutic strategies in cardiac failure.

Animals↗
PubMed1998

Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review.

Protein kinase C (PKC) has been proposed as a primary cellular mediator of ischemic preconditioning. However, the role of PKC in eliciting cardioprotection remains controversial. In this review, we summarize the evidence for and against the 'PKC hypothesis' of preconditioning, discuss the important technical limitations currently hampering PKC research, and suggest new approaches (i.e. PKC isoform-specific biochemical assays combined with immunoblotting techniques) that might aid in the definite resolution of this issue.

Animals↗
PubMed1998

Myocardial temperature reduction attenuates necrosis after prolonged ischemia in rabbits.

OBJECTIVE: Previously we observed that a large reduction in infarct size was attained by cooling the risk region of the heart, either before or early after the onset of a 30-min coronary artery occlusion. While this is a standard duration of ischemia used in the rabbit model of infarction, it may not reflect the situation of patients who are reperfused late. The effects of regional hypothermia with a longer duration of ischemia, and when the intervention is applied later, are unknown. This study tests the hypothesis that a local reduction in cardiac temperature protects myocardium during prolonged ischemia (2 h) even if begun well after coronary artery occlusion. METHODS: Anesthetized rabbits received 2 h of coronary artery occlusion and 3 h of reperfusion. Rabbits were randomly assigned to a treated group: topical myocardial cooling starting 30 min after coronary occlusion (n = 14), or control group, no intervention (n = 12). Myocardial temperature in the risk zone, hemodynamics and regional myocardial blood flow were measured. RESULTS: Ischemic zone temperature was similar in both groups at 30 min post occlusion, but the cooling maneuver produced a reduction in temperature in the risk region of the treated group such that myocardial temperature was reduced an average of 10 degrees C between 30 and 60 min of coronary artery occlusion. Myocardial temperature in the control group remained within 0.3 degree C of baseline during coronary artery occlusion and into reperfusion. Core temperatures were similar in both groups. Hemodynamic parameters and collateral blood flow during occlusion were also equivalent in both groups. After 120 min of coronary occlusion, necrosis in the control group comprised 72 +/- 3% of the ischemic risk region. However, in cooled hearts, infarct size, expressed as a fraction of the risk region was significantly lower. Infarct size in this group averaged 59 +/- 3% of the risk region (p < 0.004 vs. controls), and thus cooling resulted in a salvage of approximately 18% of the risk region. CONCLUSION: These results show that reducing myocardial temperature protects ischemic myocardium during a long duration of ischemia even if initiated after coronary artery occlusion.

Analysis of Variance↗
PubMed1998

Hypothermic, closed circuit pericardioperfusion: a potential cardioprotective technique in acute regional ischemia.

OBJECTIVES: This study sought to determine whether infarct size can be reduced by hypothermic pericardioperfusion. BACKGROUND: We have shown that myocardial infarct size can be reduced by topical cooling of the heart. The present study tests whether myocardial cooling and protection can be produced by hypothermic pericardioperfusion using a catheter. METHODS: The catheter was sutured into the pericardial space of anesthetized rabbits. Beginning 30 min before coronary artery occlusion, the space was perfused with either chilled (n = 10) or body temperature (n = 10) fluid. The artery was occluded for 30 min and reperfused for 3 h. RESULTS: After 30 min of pericardioperfusion, myocardial temperature was reduced to 34.1 +/- 0.9 degrees C in chilled hearts compared with 38.9 +/- 0.4 degrees C in control hearts, p < 0.001, a reduction in myocardial temperature of approximately 5 degrees C. Risk areas were similar in both groups (32 +/- 4% left ventricle in cooled and 31 +/- 3% in control hearts, p = NS). However, infarct size in cooled hearts was significantly reduced by 49% (18 +/- 3% of risk area vs. 35 +/- 6%, p = 0.025). Tamponade did not develop, and there were no significant differences in heart rate, arterial pressure or body temperature between groups. CONCLUSIONS: A significant reduction in myocardial temperature, without the development of cardiac tamponade, can be attained using a pericardial catheter to cool the pericardial space. This reduction in temperature causes a significant reduction in necrotic damage. This technique might be used to cool and protect the heart as an adjunct to thrombolysis or during minimally invasive cardiac surgery.

Animals↗
PubMed1998

Viagra: what every physician should know.

Viagra, an oral drug taken one hour prior to sexual activity, improves erectile function in the majority of men with erectile dysfunction who receive it. It is not an aphrodisiac and therefore will not work without sexual stimulation. The drug is absolutely contraindicated in patients on organic nitrates, as this combination can lead to severe drops in blood pressure. Patients with heart disease, suspected heart disease and risk factors for heart disease should discuss with their physicians the safety of resuming sexual activity. A cardiac work-up, including exercise treadmill testing, should be considered in appropriate patients.

Adult↗